shutterstock
Solcara Health Blog

What Happens When You Stop Semaglutide or Tirzepatide, According to the Trials

When adults stopped semaglutide in the STEP 1 trial extension, they regained about two-thirds of the weight they had lost within one year [1]. That is what happens when you stop semaglutide in the best trial data. Tirzepatide follows the same pattern. In SURMOUNT-4, people switched to placebo saw their weight rise 14.0% over 52 weeks [2].

A smiling woman with silver hair holds a dumbbell in a goblet squat on a jute rug in a bright sunroom with white shutters and pothos.

The STEP 1 extension followed 327 participants for a year after treatment, including the trial's lifestyle program, ended. By week 68, those on semaglutide 2.4 mg had lost 17.3%. After treatment stopped, they regained 11.6 percentage points by week 120, ending 5.6% below their starting weight [1]. A January 2026 BMJ meta-analysis of 37 studies put the average regain after stopping any weight-management medication at 0.4 kg per month [3].

  1. Weeks 0 to 68: 17.3% of body weight lost on semaglutide
  2. Week 68: treatment and the lifestyle program stop
  3. Week 120: 11.6 points regained, 5.6% below the starting weight

In 2021 to 2023, 40.3% of US adults had obesity [11]. About 12% of US adults said in late 2025 that they were currently taking a GLP-1 drug [12]. In a cohort of 125,474 US adults who started liraglutide, semaglutide or tirzepatide, 64.8% of those without type 2 diabetes had stopped within one year [9].

This guide reflects FDA status and published self-pay prices as of November 2026.

Stopping, tapering or staying on: what the trials say

Shows what published trials found for each path. It does not know your dose or health and is not a recommendation.

Pick the path you are considering

Stopping now

What the trials found
About two-thirds of the weight lost on semaglutide came back within a year in the STEP 1 extension. Weight rose 14.0% over 52 weeks after switching from tirzepatide to placebo in SURMOUNT-4. [1][2]
Measure first
Body composition, muscle strength and function, which the joint advisory lists as priorities when GLP-1 care starts. [19]

Planning to taper

What the trials found
No trial of gradually tapering off was found. One case series of 30 adults on every-other-week dosing had no control group. Every-other-week dosing is off-label. [21][20][28][29]
Measure first
Agree on a weight or waist check-in point with your prescriber. [21]

Staying on, possibly at a lower dose

What the trials found
Continued medication has the strongest direct evidence for limiting regain. People who stayed on tirzepatide lost another 5.5% over 52 weeks. In one randomized trial, 5 mg kept off less weight than the full dose but more than placebo. [21][2][30]
Measure first
Body composition and a strength training plan at least 3 times a week. [19]

Published trial and review data read November 2026. Do not stop, taper or change a dose without the clinician who prescribes it.

Key takeaways

  • Stopping semaglutide brought back about two-thirds of the lost weight within a year in the STEP 1 extension [1].
  • Switching from tirzepatide to placebo meant a 14.0% weight gain over 52 weeks in SURMOUNT-4, while people who stayed on it lost 5.5% more [2].
  • In the 2026 BMJ review, regain averaged 0.4 kg a month across all weight-management drugs and 0.8 kg a month for semaglutide and tirzepatide; a re-analysis of the same studies estimated 1.04 kg [3] [8].
  • About 25% of the weight lost on tirzepatide in a DXA substudy was lean mass, the same share as on placebo, and lean mass is not the same as muscle [4] [27].
  • Most trials measured stopping. One randomized trial, SURMOUNT-MAINTAIN, tested a lower tirzepatide dose: 5 mg kept off less weight than the full dose but more than placebo [30].
  • This guide puts six regain analyses in one dated table, shows which share data, and pairs them with body composition data.

Section 01 / Regain after stopping

Weight regain after stopping: STEP 1, SURMOUNT-4 and the 2026 BMJ meta-analysis

Weight regain after stopping semaglutide or tirzepatide is the return of body weight once the drug is withdrawn. Both randomized withdrawal trials in the table below found it. In STEP 4, people switched from semaglutide to placebo gained 6.9% over 48 weeks, while those who continued lost another 7.9% [6].

The Bayesian row reuses the BMJ review's semaglutide and tirzepatide studies, so those two rows are not independent.

DatasetDrugParticipantsLoss before stoppingAfter stoppingTime frame
STEP 1 extension, 2022 [1]Semaglutide 2.4 mg327 adults (both arms)17.3% at week 68Regained 11.6 percentage points, about two-thirdsWeeks 68 to 120
STEP 4, 2021 [6]Semaglutide 2.4 mg803 randomized10.6% in a 20-week run-in+6.9% on placebo vs -7.9% on semaglutideWeeks 20 to 68
SURMOUNT-4, 2024 [2]Tirzepatide 10 or 15 mg670 randomized20.9% in a 36-week lead-in+14.0% on placebo vs -5.5% on tirzepatideWeeks 36 to 88
eClinicalMedicine meta-analysis, 2025 [7]GLP-1 receptor agonists18 trials, 3,771 people (obesity, type 2 and type 1 diabetes)Varied+5.63 kg pooled in people with obesity; 8.21 kg after semaglutide vs 4.29 kg after liraglutide (subgroups)At least 12 weeks of follow-up
Bayesian re-analysis of the BMJ subgroup studies, 2026 [8]Semaglutide or tirzepatideSame 6 studies, 1,776 people15.35 kg estimated1.04 kg per month; half of the loss back by 7.5 months (projected)4 to 52 weeks observed
BMJ meta-analysis, 2026 [3]All weight-management drugs; semaglutide and tirzepatide subgroup37 studies, 9,341 people; subgroup 10 arms, 1,776 people8.3 kg all drugs; 14.7 kg subgroup0.4 kg per month all drugs (cardiometabolic markers back to baseline within 1.4 years, projected); 0.8 kg per month for semaglutide and tirzepatideAverage follow-up 32 weeks
Weight regain after GLP-1 discontinuationWhat happened after the drug stopped, six datasets, read November 9, 2026

Randomized withdrawal trials: weight change after the switch

STEP 4, switched to placebo [6]

+6.9%

STEP 4, continued semaglutide [6]

-7.9%

SURMOUNT-4, switched to placebo [2]

+14.0%

SURMOUNT-4, continued tirzepatide [2]

-5.5%

STEP 1 extension, semaglutide 2.4 mg, share of body weight

Lost by week 68 [1]

17.3%

Regained, weeks 68 to 120 [1]

11.6 percentage points

eClinicalMedicine meta-analysis, 2025: weight gained after stopping

Pooled, people with obesity [7]

+5.63 kg

Semaglutide subgroup [7]

8.21 kg

Liraglutide subgroup [7]

4.29 kg

Average regain rate after stopping, per month

BMJ 2026, all weight-management drugs [3]

0.4 kg

BMJ 2026, semaglutide and tirzepatide subgroup [3]

0.8 kg

Bayesian re-analysis of the same subgroup studies, 2026 [8]

1.04 kg

Weight regained or gained Weight lost or kept off

In every dataset, weight came back after the drug stopped.

The Bayesian row re-analyzes the BMJ review's semaglutide and tirzepatide studies, so the two rows share data. [8]

Source: STEP 1 extension, STEP 4, SURMOUNT-4, eClinicalMedicine 2025, Endocrinology, Diabetes and Metabolism 2026, BMJ 2026. Date range: 2021 to 2026 publications. Denominator: 327 + 803 + 670 participants (trials) and 3,771 + 1,776 + 9,341 (reviews; the 1,776 Bayesian participants are the BMJ subgroup, so they sit inside the 9,341). Read: 2026-11-09.

The main STEP 1 trial produced a mean change of -14.9% with semaglutide vs -2.4% with placebo at 68 weeks [5]; the extension followed a subset of those people [1].

The two monthly rates often quoted side by side are less different than they look. The BMJ review found 0.4 kg per month across every weight-management medication it pooled, and 0.8 kg per month in its semaglutide and tirzepatide subgroup of 10 study arms and 1,776 people [3]. A 2026 Bayesian re-analysis of those same six studies estimated 1.04 kg per month [8]. Its authors say study overlap "was complete by design," and that their work added modeling, not new evidence [8]. So the gap between 0.4 and 1.04 kg reflects which drugs were pooled and how the same studies were modeled, not two independent findings. The authors also warn that estimates beyond 52 weeks "were model-based extrapolations" [8].

Over 3 months, 0.4 kg per month is about 1.2 kg. At 0.8 kg per month it is about 2.4 kg, and at 1.04 kg per month about 3.1 kg. That is our calculation from the published averages, not a forecast for any one person.

Thinking about coming off a GLP-1? Ask about medical weight loss and body composition at Solcara Health before you change anything.

Section 02 / Lean mass

How much of the weight you lost was lean mass, and why that is not all muscle

In the SURMOUNT-1 body composition substudy, about 75% of the weight lost on tirzepatide was fat mass and 25% was lean mass, measured by DXA in 124 people on tirzepatide. The same 75 to 25 split held in the 36-person placebo group [4]. Lean mass is not the same as muscle. It includes muscle plus other tissue that is not fat.

A joint advisory from four lifestyle medicine, nutrition and obesity societies describes lean body mass as "including muscle and other nonfat tissues". It adds that "muscle mass is about half of lean body mass" [27].

A 2026 review of 21 randomized trials with 1,334 participants gives a different number. In its incretin-drug trials measured by DXA, fat-free mass made up 33.3% of the weight lost [15].

SourceHow it was measuredWeight-loss methodShare of loss that was lean or fat-free mass
SURMOUNT-1 substudy, 2025 [4]DXA, 124 peopleTirzepatideAbout 25% lean mass
SURMOUNT-1 substudy, 2025 [4]DXA, 36 peoplePlaceboAbout 25% lean mass
Fat-free mass meta-analysis, 2026 [15]DXA, 4 of 5 incretin trialsIncretin-based drugs33.3%
Fat-free mass meta-analysis, 2026 [15]DXA, diet-only study armsDiet alone22.3%
Fat-free mass meta-analysis, 2026 [15]DXA, diet-plus-exercise study armsDiet plus exercise7.7%

The authors, who abbreviate fat-free mass as FFM, conclude that "strategies to preserve FFM, particularly exercise, should be included in all weight-loss approaches" [15].

A trial with an older GLP-1 drug points the same way. After an 8-week diet that took off 13.1 kg, a year of exercise plus liraglutide cut body-fat percentage by 3.9 points, about twice the drop with either alone [16]. Liraglutide is a daily GLP-1 drug, so this trial is a proxy, not proof.

The joint advisory also cites modeling that puts muscle at 10% to 15% of weight lost in women and 20% to 25% in men without structured strength training [27]. Those are model estimates, not trial measurements.

Section 03 / Appetite

Why the weight comes back: appetite, not willpower

One reason weight comes back after stopping is that the body pushes to restore it. After diet-induced weight loss, appetite hormones shift toward hunger and stay shifted for at least a year. In a study of 50 adults who lost 13.5 kg on a very-low-energy diet, ghrelin rose, leptin fell, and hunger was still higher than baseline at 62 weeks [14]. That study tested diet, not a GLP-1 drug.

The authors concluded that the mediators of appetite that encourage regain "do not revert to the levels recorded before weight loss" one year later [14].

In the STEP 1 extension, cardiometabolic improvements gained on semaglutide reverted toward baseline at week 120 for most variables [1]. In the 2025 eClinicalMedicine meta-analysis, stopping a GLP-1 receptor agonist in people with obesity was followed by a pooled 5.63 kg weight gain and a 0.25% rise in HbA1c [7].

The 2026 BMJ review found regain was faster after stopping medication than after ending a behavioral weight program, by 0.3 kg per month, independent of the initial loss [3].

Inside STEP 1, people who had taken placebo regained 1.9 percentage points after the trial ended, against 11.6 points for those who had taken semaglutide [1]. The 2026 Bayesian review found that lifestyle support after stopping leaned toward slower regain, but its estimate was imprecise [8].

My view: regain after stopping is biology, not a character flaw. Planning for it works better than blaming yourself for it.

Section 04 / Tapering and lower doses

Tapering, lower doses and the evidence gap

One randomized trial has tested a lower maintenance dose. In SURMOUNT-MAINTAIN, 378 adults who lost weight on tirzepatide 10 or 15 mg continued that dose, dropped to 5 mg or switched to placebo for 52 weeks. The 5 mg group kept off less weight than the full-dose group but more than placebo [30]. No trial of gradually tapering off was found for this guide. Any dose change is a decision for your prescriber.

From the start of the trial to week 112, model-based weight change was -21.9% with the continued full dose, -16.6% after dropping to 5 mg and -9.9% after switching to placebo [30]. From week 84, people who regained more than half of their lost weight could receive rescue tirzepatide. Rescue was used by 8% of the full-dose group, 25% of the 5 mg group and 67% of the placebo group [30].

A 2026 retrospective case series looked at less frequent dosing. Thirty adults who had reached a plateau on weekly semaglutide or tirzepatide moved to reduced-frequency dosing, usually every other week, at their existing dose. Over a mean 36.3 weeks, weight went from 74.1 kg at plateau to 72.4 kg [20]. Thirty people. No control group. So it cannot show what weekly dosing or stopping would have done.

Every-other-week dosing is also off-label. The Wegovy label directs injections once weekly [28]. The Zepbound label sets maintenance doses of 5 mg, 10 mg or 15 mg once weekly [29].

A 2026 narrative perspective in Obesity Pillars says "continued obesity medication currently has the strongest direct evidence for limiting weight regain" [21]. It lists dose reduction, oral switching and less frequent dosing as possible strategies. It also says early warning signs of relapse "require prospective validation" [21].

Evidence typeExampleWhat it showsMain limit
Randomized withdrawal trialSTEP 4, SURMOUNT-4 [6] [2]Stopping leads to regain; continuing keeps weight offAbrupt switch to placebo, not a taper
Randomized dose-reduction trialSURMOUNT-MAINTAIN, 2026 [30]5 mg kept off less weight than the full dose, more than placeboTirzepatide only; one fixed lower dose
Off-treatment extensionSTEP 1 extension [1]About two-thirds of the loss back in a yearExploratory, 327 people; lifestyle support also stopped
Retrospective case seriesObesity, 2026 [20]Weight held on every-other-week dosing30 people, no control group
Narrative perspectiveObesity Pillars, 2026 [21]Continued medication has the strongest evidenceExpert opinion, not a trial

Section 05 / Before you stop

What to measure and plan before you stop

Before you stop a GLP-1, measure your starting point, build the habits linked to better maintenance, and agree on a restart plan with your prescriber. In the S-LiTE trial, one year after treatment ended, weight regain was 6.0 kg larger in people who had taken liraglutide alone than in those who had done supervised exercise [17]. S-LiTE used liraglutide, so it is a proxy here.

A marble counter set with a plate of grilled shrimp, eggs and salad, an open notebook, a glass of lemon water and a pair of small green dumbbells.
  1. Talk to your prescriber first. Do not stop, taper or skip doses on your own.
  2. Measure your body composition. The joint advisory lists muscle strength, function and body composition assessment as priorities when GLP-1 care starts [19]. InBody body composition analysis gives you a number to compare against later.
  3. Train for strength at least 3 times a week. The same advisory pairs GLP-1s with a structured exercise program that includes strength training at least 3 times weekly [19].
  4. Set a protein target. Targets of 1.2 to 1.6 g per kg of body weight per day have been proposed during active weight loss. The advisory suggests an absolute 80 to 120 g per day as an adherence aid [18]. For an 80 kg adult, 1.2 to 1.6 g/kg works out to 96 to 128 g a day (our arithmetic).
  5. Agree on a check-in point. Pick a weight or waist number with your prescriber. The 2026 perspective names weight trajectory and waist circumference as early signals, while noting they still need validation [21].
  6. If cost is the reason, price the options first. Cost is one of the reasons people cite most. In a November 2025 KFF poll, 14% of GLP-1 users said they had stopped because of cost, 13% cited side effects and 5% said their condition improved [13].

These manufacturer self-pay prices were read on November 9, 2026. NovoCare says its Wegovy prices require NovoCare home delivery or its savings offer [25].

ProductForm and doseSelf-pay priceConditions stated by the manufacturer
WegovyPen, 0.25 mg and 0.5 mg$199 a monthNew self-pay patients, first 2 monthly fills, through December 31, 2026 [25]
WegovyPen, 0.25 mg to 2.4 mg$349 a monthAfter the 2 introductory fills [25]
Wegovy HDPen, 7.2 mg$399 a monthSelf-pay [25]
WegovyTablets, 1.5 mg / 4 mg / 9 mg and 25 mg$149 / $199 / $299 a monthSelf-pay [25]
ZepboundKwikPen or 4 single-dose vials, 2.5 mg$299 a month2.5 mg is a starting dose, not a maintenance dose; not the single-dose pen [26]
ZepboundKwikPen, 5 mg$399 a monthLilly's regular 1-month KwikPen price [26]
ZepboundKwikPen, 7.5 mg / 10 mg to 15 mg$499 / $699 a month regular; as low as $449 with Lilly's offerOffer requires each refill within 45 days [26]

Novo Nordisk states its pricing will be updated after December 31, 2026 [25]. Check both pages again before you decide.

Section 06 / Questions

Stopping GLP-1 Questions Answered

How much weight do you regain after stopping semaglutide?

In the STEP 1 extension, adults regained 11.6 percentage points of the 17.3% they had lost, about two-thirds, within a year of stopping semaglutide 2.4 mg [1]. In a 2025 meta-analysis, the semaglutide subgroup regained 8.21 kg after stopping [7].

Does tirzepatide cause muscle loss?

Tirzepatide reduces lean mass along with fat. In the SURMOUNT-1 DXA substudy, about 25% of the weight lost was lean mass, the same share as on placebo [4]. Lean mass includes muscle and other nonfat tissue, so the lean-mass figure is larger than the muscle loss [27]. Strength training at least 3 times weekly is the advisory's answer [19].

Is it better to taper off a GLP-1?

SURMOUNT-MAINTAIN tested a lower dose: dropping from tirzepatide 10 or 15 mg to 5 mg kept off less weight than the full dose, but more than placebo [30]. A 30-person case series with no control group found weight held on every-other-week dosing [20], which is off-label [28] [29]. Continued medication has the strongest direct evidence [21]. Decide with your prescriber.

How fast does weight come back after stopping Zepbound?

In SURMOUNT-4, people switched from tirzepatide to placebo gained 14.0% over 52 weeks [2]. The 2026 BMJ review found 0.8 kg per month for semaglutide and tirzepatide [3], and a Bayesian re-analysis of the same studies estimated 1.04 kg per month, with half the loss back by about 7.5 months (projected) [8]. Tirzepatide looked faster before adjustment, but no clear drug difference remained after it [8]. In a large US cohort of people without type 2 diabetes, each 1% of weight regained after stopping was associated with a 2.8% higher hazard of restarting [10].

Are compounded GLP-1s still available in 2026?

FDA says semaglutide and tirzepatide are not on its drug shortage list or the 503B bulks list (page current as of April 1, 2026) [22]. On May 1, 2026, FDA proposed not to add them to that list. Comments were extended to July 30, 2026, and no later Federal Register action was found as of November 9, 2026 [23]. FDA states "compounded drugs are not FDA approved." It had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of May 31, 2026 [24].

Section 07 / Bottom line

Bottom line: plan the stop before you take it

When semaglutide or tirzepatide stops, weight comes back, about two-thirds of it within a year in the STEP 1 extension [1]. People who stayed on tirzepatide kept losing [2].

Measure your body composition, train for strength at least 3 times a week, and set a protein target [18] [19]. Then make any change with your prescriber. In the one randomized lower-dose trial, 5 mg kept off less weight than the full dose [30], and stopping brings weight back [1] [2].

Solcara Health sees patients at 496 Bramson Ct in Mount Pleasant and at The Longevity Club, 163 Rutledge Ave in downtown Charleston. To review your options for medical weight loss, call 843-981-0870 or book online. For more on measurement, read about body composition testing in Charleston, or compare semaglutide vs tirzepatide.

References

  1. [1] Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. May 2022. https://doi.org/10.1111/dom.14725
  2. [2] Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. January 2024. https://doi.org/10.1001/jama.2023.24945
  3. [3] West S et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. January 2026. https://doi.org/10.1136/bmj-2025-085304
  4. [4] Look M et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism. February 2025. https://doi.org/10.1111/dom.16275
  5. [5] Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. February 2021. https://doi.org/10.1056/NEJMoa2032183
  6. [6] Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. April 2021. https://pubmed.ncbi.nlm.nih.gov/33755728/
  7. [7] Tzang CC et al. Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. eClinicalMedicine. November 2025. https://pubmed.ncbi.nlm.nih.gov/41399474/
  8. [8] Kow CS et al. Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis. Endocrinology, Diabetes and Metabolism. September 2026. https://pubmed.ncbi.nlm.nih.gov/42673571/
  9. [9] Rodriguez PJ et al. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. JAMA Network Open. January 2025. https://pubmed.ncbi.nlm.nih.gov/39888616/
  10. [10] Rodriguez PJ et al. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists (reinitiation results). JAMA Network Open. January 2025. https://pubmed.ncbi.nlm.nih.gov/39888616/
  11. [11] CDC National Center for Health Statistics. Obesity and Severe Obesity Prevalence in Adults: United States, August 2021 to August 2023 (Data Brief No. 508). September 2024. https://www.cdc.gov/nchs/products/databriefs/db508.htm
  12. [12] KFF. Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug (KFF Health Tracking Poll). November 2025. https://www.kff.org/public-opinion/poll-1-in-8-adults-say-they-are-currently-taking-a-glp-1-drug-for-weight-loss-diabetes-or-another-condition-even-as-half-say-the-drugs-are-difficult-to-afford/
  13. [13] KFF. KFF Health Tracking Poll (reasons for stopping). November 2025. https://www.kff.org/public-opinion/poll-1-in-8-adults-say-they-are-currently-taking-a-glp-1-drug-for-weight-loss-diabetes-or-another-condition-even-as-half-say-the-drugs-are-difficult-to-afford/
  14. [14] Sumithran P et al. Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine. October 2011. https://pubmed.ncbi.nlm.nih.gov/22029981/
  15. [15] Busk-Cirera L et al. Effects of Incretin-Based Therapies, Diet and Exercise Interventions, and Bariatric Surgery on Fat-Free Mass in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis. Diabetes, Obesity and Metabolism. June 2026. https://pubmed.ncbi.nlm.nih.gov/42324178/
  16. [16] Lundgren JR et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. New England Journal of Medicine. May 2021. https://pubmed.ncbi.nlm.nih.gov/33951361/
  17. [17] Jensen SBK et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment (S-LiTE post-treatment analysis). eClinicalMedicine. February 2024. https://pubmed.ncbi.nlm.nih.gov/38544798/
  18. [18] Mozaffarian D et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from ACLM, ASN, the Obesity Medicine Association and The Obesity Society (protein). American Journal of Clinical Nutrition. May 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12612741/
  19. [19] Mozaffarian D et al. Nutritional priorities to support GLP-1 therapy for obesity (exercise and baseline assessment). American Journal of Clinical Nutrition. May 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12612741/
  20. [20] Wong M et al. Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series. Obesity. February 2026. https://pubmed.ncbi.nlm.nih.gov/41732031/
  21. [21] van Bruggen FH et al. Adaptive maintenance after incretin-induced weight loss: Moving beyond the continue-or-stop paradigm (narrative perspective). Obesity Pillars. August 2026. https://pubmed.ncbi.nlm.nih.gov/42733607/
  22. [22] U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Content current as of April 1, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  23. [23] Federal Register. List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (2026-08552, 91 FR 23431, May 1, 2026; comment extension 2026-12937, 91 FR 38719, June 26, 2026). https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
  24. [24] U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  25. [25] Novo Nordisk, NovoCare. Savings Offer Program for Wegovy (semaglutide). Read November 9, 2026. https://www.novocare.com/patient/medicines/wegovy/savings-offer.html
  26. [26] Eli Lilly and Company. Zepbound coverage and savings. Read November 9, 2026. https://zepbound.lilly.com/savings
  27. [27] Mozaffarian D et al. Nutritional priorities to support GLP-1 therapy for obesity (muscle and bone loss). American Journal of Clinical Nutrition. May 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12612741/
  28. [28] Novo Nordisk. WEGOVY prescribing information. Revised June 2026. https://www.novo-pi.com/wegovy.pdf
  29. [29] Eli Lilly and Company. ZEPBOUND prescribing information. Revised August 2026. https://pi.lilly.com/us/zepbound-uspi.pdf
  30. [30] Horn DB et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. May 2026. https://pubmed.ncbi.nlm.nih.gov/42119587/
Ashley Harwyn, PA-C, smiling in front of a woven rattan chair.

About the author

Ashley Harwyn, PA-C, ABAAHP

Full bio

This article is for general education and is not medical advice. It does not create a provider-patient relationship. Do not stop, taper or change the dose of any medication without talking to the clinician who prescribes it. Rules on prescribing and compounding vary by state; readers outside South Carolina should check with their own clinician and state board. Solcara Health, 496 Bramson Ct, Ste 120, Mount Pleasant, SC 29464 and 163 Rutledge Ave, Ste 202, Charleston, SC 29403. 843-981-0870.

Return to blog